CN112028985A - 基因工程生长因子变异体 - Google Patents

基因工程生长因子变异体 Download PDF

Info

Publication number
CN112028985A
CN112028985A CN202010915430.1A CN202010915430A CN112028985A CN 112028985 A CN112028985 A CN 112028985A CN 202010915430 A CN202010915430 A CN 202010915430A CN 112028985 A CN112028985 A CN 112028985A
Authority
CN
China
Prior art keywords
gly
glu
val
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010915430.1A
Other languages
English (en)
Chinese (zh)
Inventor
辛西娅·巴姆达德
贝努瓦·J·斯马格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of CN112028985A publication Critical patent/CN112028985A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
CN202010915430.1A 2011-05-09 2012-05-08 基因工程生长因子变异体 Pending CN112028985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
CN201280034119.XA CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280034119.XA Division CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Publications (1)

Publication Number Publication Date
CN112028985A true CN112028985A (zh) 2020-12-04

Family

ID=47139949

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010915430.1A Pending CN112028985A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体
CN201280034119.XA Pending CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280034119.XA Pending CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Country Status (8)

Country Link
US (3) US20140065113A1 (enExample)
EP (1) EP2707021B1 (enExample)
JP (5) JP2014517690A (enExample)
CN (2) CN112028985A (enExample)
AU (1) AU2012253652B2 (enExample)
CA (1) CA2835453A1 (enExample)
IL (1) IL229316B (enExample)
WO (1) WO2012154759A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736272A (zh) * 2024-02-19 2024-03-22 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830503A1 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
IL307628A (en) * 2013-02-20 2023-12-01 Minerva Biotechnologies Corp Nme inhibitors and methods of using nme inhibitors
JP2018501539A (ja) * 2014-10-16 2018-01-18 カウンシル, インコーポレイテッド バリアントコーラー
KR20230028796A (ko) 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
AU2023253692A1 (en) 2022-04-12 2024-11-14 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228357A1 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20070009918A1 (en) * 1996-04-23 2007-01-11 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0495910T3 (da) * 1989-10-18 2002-01-14 Us Health Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
ES2317843T3 (es) * 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
EP1334127A1 (en) * 2000-11-02 2003-08-13 Maxygen Aps Single-chain multimeric polypeptides
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002306921A1 (en) * 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Fc(FSH−Fc)融合タンパク質
EP3805269A1 (en) * 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TGF-β 길항제 다중-표적 결합 단백질
US11898160B2 (en) * 2008-10-09 2024-02-13 Minerva Biotechnologies Corporation Method for maintaining pluripotency in cells
KR20190122749A (ko) * 2009-06-11 2019-10-30 미네르바 바이오테크놀로지 코포레이션 줄기세포 및 전구세포를 배양하는 방법
US20130040845A1 (en) * 2010-02-16 2013-02-14 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
CA2830503A1 (en) * 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009918A1 (en) * 1996-04-23 2007-01-11 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20060228357A1 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736272A (zh) * 2024-02-19 2024-03-22 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Also Published As

Publication number Publication date
CN103930439A (zh) 2014-07-16
EP2707021A2 (en) 2014-03-19
US20200062812A1 (en) 2020-02-27
CA2835453A1 (en) 2012-11-15
EP2707021B1 (en) 2024-02-21
JP2020039359A (ja) 2020-03-19
AU2012253652A1 (en) 2013-11-28
AU2012253652B2 (en) 2017-07-06
WO2012154759A3 (en) 2014-05-01
JP2022031824A (ja) 2022-02-22
US20140065113A1 (en) 2014-03-06
EP2707021C0 (en) 2024-02-21
WO2012154759A2 (en) 2012-11-15
JP6717725B2 (ja) 2020-07-01
IL229316A0 (en) 2014-01-30
JP2014517690A (ja) 2014-07-24
US20240294590A1 (en) 2024-09-05
IL229316B (en) 2020-02-27
JP2024056702A (ja) 2024-04-23
EP2707021A4 (en) 2015-08-05
JP2017061471A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
JP6486686B2 (ja) 単鎖抗体及び他のヘテロ多量体
JP4035400B2 (ja) 生体内エリスロポエチン活性が増進した融合蛋白質
EP2992021B1 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
KR20200119251A (ko) 트랜스페린 수용체-결합 폴리펩타이드 및 이의 용도
TWI237056B (en) Fusion protein having enhanced in vivo activity of erythropoietin
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
CN110337444B (zh) 穿越血脑屏障的纳米药物载体
RS58839B1 (sr) Muteini lipokalina u suzama koji vezuju il-4 r alfa
AU2013365796B2 (en) Stabilized insulin-like growth factor polypeptides
CN104878064A (zh) 糖蛋白的产生
AU2019306821B2 (en) Solubilized apyrases, methods and use
AU2020243073B2 (en) Recombinant CCN domain proteins and fusion proteins
KR20200107842A (ko) 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
CN105399832A (zh) 一种无标签单链型人源双特异性抗体及其用途
WO2022191253A1 (ja) 融合タンパク質の製造方法
EP4480964A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
CN111479820A (zh) 重组多肽中的工程化o-糖基化及其用途
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
WO2013157973A1 (en) Genetically modified recombinant fibroblast growth factor (fgf1) conjugated with metal or metal oxide nanoparticles, its dna and amino acid sequences and use
CN109748969A (zh) 一种二聚体化融合蛋白及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination